Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Cancer Treatment Reviews|July 16, 2008
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancerRoberto Petrioli, Anna Ida Fiaschi, Edoardo Francini, et al.
Medicine|December 16, 2014
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancerEdoardo Francini, Roberto Petrioli, Anna Ida Fiaschi, et al.
Urology|February 3, 2007
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancerRoberto Petrioli, Loretta Paolelli, Edoardo Francini, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2015
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetateRoberto Petrioli, Edoardo Francini, Letizia Laera, et al.
Journal of the American Dental Association (1939)|May 3, 2011
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumabFilippo Francini, Alessandra Pascucci, Edoardo Francini, et al.
Anti-Cancer Drugs|June 9, 2015
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experienceEdoardo Francini, Anna I Fiaschi, Roberto Petrioli, et al.
Cancer Biology & Therapy|September 30, 2015
An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancerGiandomenico Roviello, Edoardo Francini, Armando Perrella, et al.
Clinical Colorectal Cancer|March 18, 2018
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of ChemotherapyRoberto Petrioli, Martina Chirra, Luciana Messuti, et al.
Prostate Cancer and Prostatic Diseases|September 5, 2020
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastasesBradley McGregor, Li Zhang, Kathryn P Gray, et al.
Anti-Cancer Drugs|March 27, 2015
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancerRoberto Petrioli, Giandomenico Roviello, Anna I Fiaschi, et al.
Pageof 8